New User:

Forgot your password?

Stock Market & Financial Investment News

News For GOL;HNR;MDCO;DSW From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 18, 2014
09:21 EDTGOLOn The Fly: Pre-market Movers
Subscribe for More Information
07:01 EDTMDCOThe Medicines Co., SciClone establish strategic partnership
The Medicines Company (MDCO) and SciClone Pharmaceuticals (SCLN) announced the establishment of a strategic partnership for two cardiovascular products in China. The partnership includes an agreement granting SciClone a license and the exclusive rights in China to promote two products of The Medicines Company: ANGIOMAX for Injection, an anticoagulant indicated in patients undergoing percutaneous coronary intervention with provisional use of glycoprotein IIb/IIIa inhibitor and in patients with, or at risk of, heparin-induced thrombocytopenia and thrombosis syndrome undergoing PCI. A Phase 3 registration trial was completed in China and is currently under review by the China Food and Drug Administration for marketing approval. CLEVIPREX Injectable Emulsion, a third-generation dihydropyridine calcium channel blocker indicated for the reduction of blood pressure when oral therapy is not feasible or desirable. The clinical trial application for China was filed in 2013. Under the terms of the agreement, SciClone will be responsible for all aspects of commercialization, including pre- and post-launch activities, for both products in the China market excluding Hong Kong and Macau. SciClone has also agreed to assist in the China registration process for both products. Financial terms of the agreement, in addition to net sales royalties payable to The Medicines Company, include the following additional payments to The Medicines Company: an upfront payment; a product support services fee; and regulatory/commercial success milestone payments of up to an aggregate of $50.5M.
06:50 EDTGOLGOL Linhas upgraded to Buy from Neutral at BofA/Merrill
Subscribe for More Information
December 17, 2014
08:17 EDTGOLGOL Linhas reports November domestic load factor reached 79.9%
GOL Linhas reported its domestic load factor reached 79.9% in November, 3.7p.p. more than in the same month last year, while the year-to-date figure stood at 77.5%. Domestic demand increased by 6% in the month and 7.8% year-to-date. Domestic supply climbed by 1.2% in the month. Capacity in the domestic market declined by 2.3% year to date, in line with the company's 2014 guidance of a reduction between -3% and -1%. In November, the number of paid passengers transported in the domestic market totaled 3.2M, 5.1% up on the same month last year. International demand grew by 25.7% in November, leading to a 1.6p.p. increase in the month's load factor to 69.2%.
December 11, 2014
10:13 EDTGOLOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:02 EDTMDCOAlnylam, The Medicines Co. announce initiation of Phase 1 ALN-PCSsc trial
Subscribe for More Information
06:42 EDTGOLGOL Linhas upgraded to Overweight from Neutral at JPMorgan
JPMorgan upgraded GOL Linhas to Overweight saying lower fuel prices should increase margins in 2015. The firm finds shares attractively valued and expects consensus estimates to move higher. The Brazil-based airliner closed yesterday down 5c to $5.47.
December 10, 2014
10:33 EDTDSWDSW management to meet with MKM Partners
Subscribe for More Information
December 8, 2014
12:25 EDTMDCOAntibiotic makers rise after Merck agrees to buy Cubist
Subscribe for More Information
10:11 EDTMDCOHigh option volume stocks
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use